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Abstract 
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape 
of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to 
procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest 
development in idarucizumab, andexanet alpha and PER977.
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Background
Warfarin, a vitamin K antagonist (VKA), was the only 
oral anticoagulant for more than half a century [1]. There 
were various limitations like its narrow therapeutic index, 
food and drug interactions, need for regular monitoring 
and frequent dose adjustments. These drawbacks and 
limitations fuelled the development of newer agents [2]. 
In 2010, dabigatran, a direct thrombin inhibitor, became 
the first target specific anticoagulant approved by FDA 
[3]. It was soon followed by Factor Xa inhibitors-rivar-
oxaban and apixaban [4, 5]. Edoxaban has most recently 
joined the rest [6, 7].
They have been approved for prevention of stroke in 
nonvalvular atrial fibrillation, and recently in preven-
tion of recurrent deep vein thrombosis and pulmonary 
embolism. These drugs are prescribed in fixed doses and 
have fewer incidents of intracranial hemorrhage in com-
parison to warfarin in large randomized phase III stud-
ies [8]. Nevertheless bleeding is still a relevant side effect 
and their biggest drawback has been the lack of a reliable 
reversible agent [9]. Unlike warfarin, there is no antidote 
for these newer agents. Currently there are a few prom-
ising antidotes undergoing clinical trials. These include 
idarucizumab, andexanet alpha and PER977 [10].
In this review we summarized studies on antidotes to 
the target specific oral anticoagulants, their mechanism 
of action and their potential in changing the future of 
anticoagulation.
Target specific oral anticoagulants and the risk of bleeding
The development of TSOAs accelerated in the last dec-
ade. Various trials comparing warfarin to either dabi-
gatran or any of the Factor Xa inhibitors proved that 
the newer agents had significantly lower bleeding risk 
[11, 12]. Ruff et  al. did a meta-analysis comparing the 
safety and efficacy of the four newer oral agents to war-
farin in patients with atrial fibrillation. They were found 
to be equally effective in the prevention of stroke. More 
importantly the incidence of intracranial hemorrhage 
was reduced by almost 50 % and there was a significant 
reduction in all cause mortality. However, an increase 
in gastrointestinal bleeding was observed [13]. Kham 
recently reported a case of spontaneous cardiac tampon-
ade within 10  days of starting rivaroxaban on a patient 
[14]. Certain groups of patients on anticoagulation, such 
as the elderly with a fall, or those needing emergent 
surgeries or encountering trauma will need immediate 
reversal of anticoagulation [15]. This lack of antidote lim-
its the use of TSOAs despite their many benefits.
At present, reversal of TSOAs is usually attempted by 
the administration of prothrombin complex concentrates 
(PCC). They contain Factor II, IX and X. The four Factor 
PCC also contains Factor VII. These agents are supposed 
to reverse the effect of the novel oral anticoagulants by 
saturating their action. However this rationale is yet to be 
proven by studies. Also this method does not neutralize 
the risk of thromboembolism [16].
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Dabigatran and idarucizumab
Dabigatran is a direct thrombin inhibitor administered 
as a low molecular weight prodrug dabigatran etex-
ilate mesylate. After oral administration it converts to 
dabigatran, which is a reversible inhibitor of activated 
thrombin. With the RE-LY trial, dabigatran became the 
first FDA approved oral anticoagulant for the preven-
tion of systemic thromboembolism and stroke in non-
valvular atrial fibrillation [17, 18]. Since then there have 
been noticeable incidents of bleeding. In a recent study 
comparing the risk of bleeding of dabigatran to warfarin, 
dabigatran was found to have an increased risk of major 
bleeding including gastrointestinal bleeds but a lower 
risk of intracranial hemorrhage [19]. Hemodialysis has 
been shown to clear 50–60 % of dabigatran and has been 
used to rapidly reduce massive bleeding [20], but stand-
ard hemodialysis is not a practical option in unstable 
conditions, where continuous venovenous hemodialysis 
has been successfully used [17, 21].
Idarucizumab (aDabi-Fab, BI 655075, UNII-
97RWB5S1U6) is the first dabigatran specific antidote 
under study. It is a humanized monoclonal antibody frag-
ment [Fab] that binds specifically to dabigatran (Fig.  1). 
It has an affinity for dabigatran that is ~350 times greater 
than that of thrombin. In ex  vivo studies in rats, steady 
state dabigatran levels of ~200  ng were completely 
reversed within 1 min of an intravenous bolus of idaru-
cizumab. Strong similarities were noted in the binding 
pattern of idarucizumab to dabigatran and thrombin to 
dabigatran. But idarucizumab lacks thrombin like enzy-
matic activity and does not bind thrombin substrates. 
Therefore it does not functionally resemble thrombin 
[22]. A phase 1, first-in-human, single-rising-dose, ran-
domized, placebo-controlled trial in 110 healthy volun-
teers (27 placebo, 83 idarucizumab) was conducted to 
assess the pharmacokinetics, safety and tolerability of 
idarucizumab [23]. Idarucizumab was found to attain 
peak plasma levels rapidly. However its concentration 
decreased to 5 % or less of the peak level within 4 h sec-
ondary to renal elimination. It was found that it had to be 
dosed in 1:1 ratio with dabigatran for its complete effi-
cacy. Also of importance is the fact that it had no impact 
on the coagulation profile of subjects who received pla-
cebo [23]. A phase 3 trial has been ongoing to evaluate 
the reversal of the anticoagulant effects of dabigatran by 
idarucizumab in patients treated with dabigatran who 
have uncontrolled bleeding or require emergency sur-
geries or procedures (REVERSE AD trial) [24–27]. An 
interim analysis showed that the anticoagulant effect of 
dabigatran was completely reversed within minutes by 
idarucizumab. This interim analysis included 90 patients. 
Fig. 1 Idarucizumab binds and inactivates dabigatran. Idarucizumab 
is the first-in-class dabigatran-specific antidote. It is a humanized 
monoclonal antibody fragment [Fab] that binds specifically to and 
inactivates dabigatran
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The primary end point of this study was the maximum 
percentage reversal of the anticoagulant effect of dabi-
gatran within 4  h after the administration of 5  g of IV 
idarucizumab. This was determined by measuring the 
dilute thrombin time (elevated in 68 patients in the anal-
ysis) or ecarin clotting time (elevated in 81 patients) at 
a central laboratory. The median maximum percentage 
reversal was 100 % (95 % confidence interval, 100–100) in 
these patients with elevated coagulation profile [28].
Factor Xa inhibitors and andexanet alfa
A recent analytical study was conducted in Germany 
using data from a prospective, noninterventional oral 
anticoagulation registry. 43  % of the 1776 patients on 
rivaroxaban reported bleeding and of those 6.1  % were 
classified as major bleeding [29].
Andexanet alfa (PRT064445, r-Antidote; Portola Phar-
maceuticals) is a 39 kDa, recombinant modified decoy of 
Factor Xa produced in Chinese hamster ovary cells. The 
amino acid serine is replaced by alanine at position 419. 
This recombinant protein retains the ability to bind direct 
FXa inhibitors as well as antithrombin activated by low 
molecular weight heparin or fondaparinux [30]. There 
was some concern that it could compete and hinder the 
function of Factor Xa in an active coagulation thus affect-
ing hemostasis. Andexanet lacks the membrane-binding 
γ-carboxyglutamic acid domain (Gla domain) of Factor 
Xa which prevents its binding to the phospholipid mem-
brane of cells (Fig. 2). This property thus allows the acti-
vation of Factor Xa by tissue factor and Factor VIIa via 
the extrinsic pathway [8, 30].
In a preclinical study in a rabbit model, andexanet 
alfa was found to reverse the action of direct Factor Xa 
inhibitors in a dose dependent manner [31]. The phase II 
studies with rivaroxaban and apixaban demonstrated a 
decrease in activity of Factor Xa by 53 and 20 % respec-
tively. In a phase 2 randomized, double blind, placebo-
controlled trial of andexanet, preliminary reports showed 
that a bolus dose of andexanet α antagonized the anti-Xa 
activity of apixaban and rivaroxaban (5  mg twice daily, 
11 doses) in healthy subjects [32–35]. At present rand-
omized placebo controlled double-blinded phase 3 trials 
are ongoing to evaluate the safety and efficacy of andexa-
net alfa in reversing apixaban- (ANNEXA-A study) and 
rivaroxaban-(ANNEXA-R study) induced anticoagula-
tion in healthy volunteers.
Target specific oral anticoagulants and PER977
PER977 (arapazine, ciraparantag; Perosphere Inc.) is a 
small, 512  Da, synthetic, water soluble molecule that 
binds to direct inhibitors of factor Xa and IIa as well as 
to heparin-based anticoagulants through non-covalent 
hydrogen bonding and charge interactions. It is reported 
to antagonize the effects of all anticoagulants except 
VKAs and agratroban [8, 30].
In an animal model, rats were overdosed with rivar-
oxaban, apixaban, edoxaban and dabigatran. PER977 was 
noted to reduce bleeding within 30 min of administration 
[36].
In the first human trial of PER977 (NCT01826266), the 
pharmacokinetics and pharmacodynamics were studied 
Fig. 2 Andexanet alpha is a recombinant protein that binds to and 
inactivates direct factor Xa inhibitors. Andexanet lacks the mem-
brane-binding γ-carboxyglutamic acid domain (Gla domain) of factor 
Xa, therefore lacks binding to the phospholipid membrane of cells
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with escalating doses of PER977 (100–300  mg). It was 
tested on volunteers who were either untreated or pre-
treated with 60  mg of edoxaban. A dose of intravenous 
bolus of 300 mg PER977 was found to normalize whole 
blood clotting time within 10–30 min and the effect was 
sustained for over 24 h [37].
Conclusion
Target specific oral anticoagulants represent a new era 
in anticoagulation. The major drawback is the absence 
of an effective antidote. With the ongoing clinical trials 
and preliminary results from the trials [28, 37], effective 
antidotes that can successfully reverse the effects of these 
novel anticoagulants may become available in the near 
future.
Authors’ contributions
DL designed the study. AD and DL drafted the manuscript. Both authors read 
and approved the final manuscript.
Author details
1 Department of Medicine, New York Medical College and Westchester Medi-
cal Center, Valhalla, NY 10595, USA. 2 Henan Cancer Hospital and the Affiliated 
Cancer Hospital of Zhengzhou University, Zhengzhou, China. 
Acknowledgements
This study was partly supported by Henan Cancer Hospital and the Affiliated 
Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 20 July 2015   Accepted: 25 August 2015
References
 1. Mueller RL, Scheidt S. History of drugs for thrombotic disease. Dis-
covery, development, and directions for the future. Circulation. 
1994;89(1):432–49.
 2. Robert F. The potential benefits of low-molecular-weight heparins in 
cancer patients. J Hematol Oncol. 2010;3:3.
 3. Redondo S, Martinez MP, Ramajo M, Navarro-Dorado J, Barez A, Tejerina 
T. Pharmacological basis and clinical evidence of dabigatran therapy. J 
Hematol Oncol. 2011;4:53.
 4. Arepally GM, Ortel TL. Changing practice of anticoagulation: will target-
specific anticoagulants replace warfarin? Annu Rev Med. 2015;66:241–53.
 5. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assess-
ment of oral antiplatelet and anticoagulant treatments. Lancet. 
2015;386(9990):281–91.
 6. Buller H, Investigators H-V. Edoxaban versus warfarin for the treat-
ment of symptomatic venous thromboembolism. N Engl J Med. 
2013;369(15):1406–15.
 7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, 
et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J 
Med. 2013;369(22):2093–104.
 8. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview 
of current developments. Thromb Haemost. 2015;113(5):931–42.
 9. Siegal DM, Garcia DA, Crowther MA. How I treat target-specific oral 
anticoagulant—associated bleeding. Blood. 2014;123(8):1152–8.
 10. Bauer KA. Targeted anti-anticoagulants. N Engl J Med. 2015;373:569–71.
 11. van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct 
oral anticoagulants compared with vitamin K antagonists for acute 
venous thromboembolism: evidence from phase 3 trials. Blood. 
2014;124(12):1968–75.
 12. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, 
et al. Major bleeding in patients with atrial fibrillation receiving apixaban 
or warfarin: the ARISTOTLE Trial (apixaban for reduction in stroke and 
other thromboembolic events in atrial fibrillation): predictors, characteris-
tics, and clinical outcomes. J Am Coll Cardiol. 2014;63(20):2141–7.
 13. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekow-
itz MD, et al. Comparison of the efficacy and safety of new oral antico-
agulants with warfarin in patients with atrial fibrillation: a meta-analysis of 
randomised trials. Lancet. 2014;383(9921):955–62.
 14. Kham NM, Song M. Spontaneous, life-threatening hemorrhagic 
cardiac tamponade secondary to rivaroxaban. Am J Ther. 2015;22:PMID 
26035030.
 15. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy 
and safety of apixaban compared with warfarin according to age for 
stroke prevention in atrial fibrillation: observations from the ARISTOTLE 
trial. Eur Heart J. 2014;35(28):1864–72.
 16. Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grottke O. 
Reversal of dabigatran anticoagulation ex vivo: porcine study comparing 
prothrombin complex concentrates and idarucizumab. Thromb Haemost. 
2015;113(4):728–40.
 17. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin 
inhibitor. Circulation. 2011;123(13):1436–50.
 18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, 
et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J 
Med. 2009;361(12):1139–51.
 19. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran 
in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24.
 20. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. 
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage mas-
sive dabigatran-associated postcardiac surgery bleeding. Blood. 
2012;119(9):2172–4.
 21. Paul S, Hamouda D, Prashar R, Mbaso C, Khan A, Ali A, et al. Management 
of dabigatran-induced bleeding with continuous venovenous hemodi-
alysis. Int J Hematol. 2015;101(6):594–7.
 22. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A 
specific antidote for dabigatran: functional and structural characteriza-
tion. Blood. 2013;121(18):3554–62.
 23. Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. 
A randomised study in healthy volunteers to investigate the safety, 
tolerability and pharmacokinetics of idarucizumab, a specific antidote to 
dabigatran. Thromb Haemost. 2015;113(5):943–51.
 24. Pinto I, Giri A, Arshad U, Gajra A. New Oral Anticoagulants and Their 
Reversal. Curr Drug Saf. 2015;10:PMID 25877809.
 25. Pollack CV. New oral anticoagulants in the ED setting: a review. Am J 
Emerg Med. 2012;30(9):2046–54.
 26. Pollack CV. Coagulation assessment with the new generation of oral anti-
coagulants. Emerg Med J. 2015;32. doi:10.1136/emermed-2015-204891.
 27. Pollack CV, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, et al. 
Design and rationale for RE-VERSE AD: a phase 3 study of idaruci-
zumab, a specific reversal agent for dabigatran. Thromb Haemost. 
2015;114(1):198–205.
 28. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bern-
stein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 
2015;373:511–20.
 29. Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, 
et al. Rates, management, and outcome of rivaroxaban bleeding in daily 
care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–62.
 30. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, 
Vargas-Castrillon E. Specific antidotes in development for reversal of 
novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 
2014;9(1):2–10.
 31. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A 
specific antidote for reversal of anticoagulation by direct and indirect 
inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51.
 32. Crowther M KM, Lorenz T, Mathur V, Lu G, Hutchaleelaha A, et al. A phase 
2 randomized, double-blind, placebo-controlled trial of PRT064445, a 
Page 5 of 5Das and Liu  Exp Hematol Oncol  (2015) 4:25 
novel, universal antidote for direct and indirect factor Xa inhibitors. J 
Thromb Haemost. 2013;11(Suppl 2): AS20.1.
 33. Crowther M LG, Lu G, Conley PB, Castillo J, Hollenbach S, et al. Reversal of 
enoxaparin-induced anticoagulation in healthy subjects by andexanet 
alfa (PRT064445), an antidote for direct and indirect FXa inhibitors—a 
phase 2 randomized, double-blind, placebo- controlled trial. J Thromb 
Haemost. 2014;12(Suppl 1): COA01 (abstract).
 34. Crowther M LG, Conley P, Hollenbach S, Castillo J, Lawrence, J, et al. 
Sustained reversal of apixaban anticoagulation with andexanet alfa using 
a bolus plus infusion regimen in a phase 2 placebo controlled trial. Eur 
Heart J 2014;35(Suppl.1): P738 (abstract).
 35. Crowther MMV, Kitt M, Lu G, Conley PB, Hollenbach S, et al. A phase 2 ran-
domized, double blind, placebo-controlled trial demonstrating reversal 
of rivaroxaban-induced anticoagulation in healthy subjects by andexanet 
alfa (PRT064445), an antidote for Fxa inhibitors. Blood. 2013;122(21):3636.
 36. Bakhru S, Laulicht B, Jiang X, Chen L, Pan D, Grosso M, et al. PER977: a 
synthetic small molecule which reverses over-dosage and bleeding by 
the new oral anticoagulants. Ciuculation. 2013;128:A18809.
 37. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use 
of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 
2014;371(22):2141–2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
